CHANGES IN HRCT SPIROMETRY AND CLINICAL SYMPTOM IN SCLERODERMA PATIENTS’ TREATMENT WITH INTRAVENOUS CYCLOPHOSPHAMIDE

Hajialilo, M and Taghizadeieh, A and Khabbazi, A.R and Ghorbani Haghjo, A and Asadzadeh, M (2016) CHANGES IN HRCT SPIROMETRY AND CLINICAL SYMPTOM IN SCLERODERMA PATIENTS’ TREATMENT WITH INTRAVENOUS CYCLOPHOSPHAMIDE. The Journal of Urmia University of Medical Sciences, 27 (6). pp. 466-475.

[img]
Preview
Text
3 Hajalilou-2343-1.pdf

Download (504kB) | Preview

Abstract

Scleroderma is a systemic condition with various manifestations in different organs. Among these organs, the lungs are affected very frequently, and the involvement is progressive and significant. Various medications have been suggested and tested in patients with scleroderma and lung involvement, but their efficacy and safety profile differ and enforce a difficult final decisionmaking. Since cyclophosphamide is an example of this kind, this study sought to examine the therapeutic effect of this drug in patients with scleroderma and lung disease. Materials & Methods: A total of 20 patients with scleroderma and lung parenchymal disease received intravenous cyclophosphamide (750 mg/m2) along with gradually tapering prednisolone (20-7.5 mg/day) and azathioprine (2mg/kg) after discontinuation of the former for six consecutive months. The Transition Dyspnea Index (TDI), Forced Vital Capacity (FVC), Total Lung Capacity (TLC), 17 revised Rodnan Score were examined three and six months after starting the treatment. Results: Six months after treatment, significant changes in FVC (p = 0.55), TLC (p = 0.39), FEV1 (p=0.27), 17 revised Rodnan Score (p=0.98) was not observed. The TDI also did not show significant changes during the six months of treatment (p = 0.79). Based on the type of antibody was not seen significant difference in the amount of TDI. Conclusion: Administration of intravenous cyclophosphamide in the treatment of scleroderma in patients with pulmonary involvement of our study did not have considerable effects on pulmonary function and clinical manifestations that were similar to other studies in this field.

Item Type: Article
Uncontrolled Keywords: Scleroderma, Lung Disease, Cyclophosphamide
Subjects: R Medicine > R Medicine (General)
Depositing User: Unnamed user with email gholipour.s@umsu.ac.ir
Date Deposited: 23 Sep 2017 06:31
Last Modified: 24 Feb 2019 08:00
URI: http://eprints.umsu.ac.ir/id/eprint/2981

Actions (login required)

View Item View Item